학술논문
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Document Type
Article
Author
Source
In The Lancet Oncology June 2020 21(6):763-775
Subject
Language
ISSN
1470-2045